New hope for head and neck cancer patients who stopped responding to immunotherapy
Disease control
Recruiting now
This study tests a new oral drug (NRC-2694-A) taken with chemotherapy (paclitaxel) in people with advanced head and neck cancer that has returned or spread and no longer responds to immunotherapy. About 21 adults will participate to see if the combination shrinks tumors. The goal…
Phase: PHASE2 • Sponsor: NATCO Pharma Ltd. • Aim: Disease control
Last updated May 17, 2026 04:16 UTC